FDA bars new patients from joining study of diabetes drug tied to heart risks

WASHINGTON - U.S. federal health officials are barring new patients from enrolling in a safety study of GlaxoSmithKline's controversial diabetes pill Avandia, a week after a panel of experts ruled that the drug increases heart risks....More